CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

abrocitinib

Last Updated: March 26, 2021
Result type: Reports
Project Number: SR0686-000
Product Line: Reimbursement Review

Generic Name: abrocitinib

Brand Name: TBC

Manufacturer: Pfizer Canada ULC

Therapeutic Area: Atopic dermatitis, moderate to severe

Indications: ​For the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, including the relief of pruritus, who have had an inadequate response to prescribed topical therapy or for whom these treatments are not advisable. Abrocitinib can be used with or without medicated topical therapies for atopic dermatitis.

Manufacturer Requested Reimbursement Criteria1: ​As per the label: For the treatment of patients aged 12 years and older with moderate-to-severe AD, including the relief of pruritus, who have had an inadequate response to prescribed topical therapy or for whom these treatments are not advisable. Abrocitinib can be used with or without medicated topical therapies for atopic dermatitis.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: March 26, 2021

Call for patient/clinician input closed: May 21, 2021

Anticipated Date: April 26, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback